Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC13332Aurora A Inhibitor ICAS: 1158838-45-9纯度: >99.00%
A potent and selective inhibitor of Aurora A kinase
- GC13442Sanguinarine chlorideCAS: 5578-73-4纯度: >99.00%
A natural alkaloid with anti-inflammatory and anti-oxidant properties
- GC13484GriseofulvinCAS: 126-07-8纯度: >98.50%
A fungal metabolite with antifungal and anticancer activities
- GC13508Trametinib (GSK1120212)CAS: 871700-17-3纯度: >98.00% / >99.00%
Trametinib (GSK1120212, JTP-74057) 是第二代 MEK 激酶小分子抑制剂。
- GC13580Rigosertib sodiumCAS: 592542-60-4纯度: >98.50%
Rigosertib sodium (ON-01910 sodium) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3K/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib sodium 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。
- GC13601Everolimus (RAD001)CAS: 159351-69-6纯度: >98.00%
依维莫司 (RAD001) 是一种具有口服活性的雷帕霉素衍生物,可抑制 Ser/Thr 激酶 mTOR(雷帕霉素的哺乳动物靶标)。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC13292 | EGTA | 67-42-5 | >98.00% / >99.00% | |
A chelating agent | ||||
| GC13332 | Aurora A Inhibitor I | 1158838-45-9 | >99.00% | |
A potent and selective inhibitor of Aurora A kinase | ||||
| GC13339 | Ketoprofen | 22071-15-4 | >99.50% | |
A non-selective COX inhibitor | ||||
| GC13359 | Topotecan HCl | 119413-54-6 | >99.00% | |
Topotecan HCl是一种毒药类的拓扑异构酶I抑制剂。 | ||||
| GC13383 | EPZ004777 | 1338466-77-5 | >98.00% | |
EPZ004777 作为一种有效的表观遗传调节剂,可以逆转 TGF-β1 诱导的 T 调节细胞,可用于治疗多种免疫疾病。 | ||||
| GC13394 | Ispinesib (SB-715992) | 336113-53-2 | >98.00% | |
An Eg5 inhibitor | ||||
| GC13400 | Ac-VDVAD-AFC | 210344-94-8 | - | |
A fluorogenic substrate for caspase-2 | ||||
| GC13408 | CI994 (Tacedinaline) | 112522-64-2 | >98.00% | |
An inhibitor of HDAC1, -2, and -3 | ||||
| GC13410 | Masitinib (AB1010) | 790299-79-5 | >99.50% | |
An inhibitor of c-Kit | ||||
| GC13433 | AZ 960 | 905586-69-8 | >98.00% | |
A JAK2 inhibitor | ||||
| GC13442 | Sanguinarine chloride | 5578-73-4 | >99.00% | |
A natural alkaloid with anti-inflammatory and anti-oxidant properties | ||||
| GC13474 | Garcinol | 78824-30-3 | >95.00% | |
Garcinol是组蛋白乙酰转移酶p300和PCAF的非特异性抑制剂,IC 50 分别为7μM和5μM。 | ||||
| GC13484 | Griseofulvin | 126-07-8 | >98.50% | |
A fungal metabolite with antifungal and anticancer activities | ||||
| GC13502 | Cysteamine HCl | 156-57-0 | >98.00% | |
A radioprotective aminothiol | ||||
| GC13508 | Trametinib (GSK1120212) | 871700-17-3 | >98.00% / >99.00% | |
Trametinib (GSK1120212, JTP-74057) 是第二代 MEK 激酶小分子抑制剂。 | ||||
| GC13526 | Spautin-1 | 1262888-28-7 | >99.00% | |
Spautin-1可抑制去泛素化酶USP10和USP13的活性,IC 50 值为0.6-0.7μM。 | ||||
| GC13544 | Voreloxin | 175414-77-4 | - | |
An inhibitor of topoisomerase II | ||||
| GC13568 | SecinH3 | 853625-60-2 | >99.50% | |
A selective inhibitor of cytohesins | ||||
| GC13580 | Rigosertib sodium | 592542-60-4 | >98.50% | |
Rigosertib sodium (ON-01910 sodium) 是一种多激酶抑制剂和选择性抗癌剂,通过抑制 PI3K/Akt 通路诱导细胞凋亡,促进组蛋白 H2AX 的磷酸化并诱导细胞周期 G2/M 停滞。 Rigosertib sodium 是一种选择性和非 ATP 竞争性的 PLK1 抑制剂,IC50 为 9 nM。 | ||||
| GC13590 | SJ 172550 | 431979-47-4 | >98.00% | |
A small molecule inhibitor of MDMX | ||||
| GC13592 | PD173955 | 260415-63-2 | >99.00% | |
A tyrosine kinase inhibitor | ||||
| GC13598 | MGCD-265 | 875337-44-3 | >98.50% | |
A c-Met and VEGFR2 inhibitor | ||||
| GC13601 | Everolimus (RAD001) | 159351-69-6 | >98.00% | |
依维莫司 (RAD001) 是一种具有口服活性的雷帕霉素衍生物,可抑制 Ser/Thr 激酶 mTOR(雷帕霉素的哺乳动物靶标)。 | ||||
| GC13614 | Mycophenolate Mofetil | 128794-94-5 | >99.50% | |
A prodrug form of mycophenolic acid | ||||
